Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: Results from the ovarian cancer association consortium

Twin Research and Human Genetics

Volumn 12, Issue 3, 2009, Pages 269-275

  Johnatty, Sharon E ^a   Beesley, Jonathan ^a   Chen, Xiaoqing ^a   Spurdle, Amanda B ^a   DeFazio, Anna ^b   Webb, Penelope M ^a   Goode, Ellen L ^c   Rider, David N ^c   Vierkant, Robert A ^c   Anderson, Stephanie ^c   Wu, Anna H ^d   Pike, Malcolm ^d   Van Den Berg, David ^d   Moysich, Kirsten ^e   Ness, Roberta ^f   Doherty, Jennifer ^g   Rossing, Mary Anne ^g   Pearce, Celeste Leigh ^d   Chenevix Trench, Georgia ^a,h  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Basic fibroblast growth factor; FGF2; Ovarian cancer; Polymorphisms; Serous

Indexed keywords

FIBROBLAST GROWTH FACTOR 2;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FGF2 GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; OVARY CARCINOMA; POPULATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; UNITED STATES;

AUSTRALIA; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; POPULATION GROUPS; RISK FACTORS; SEROUS MEMBRANE; UNITED STATES;

EID: 67249140681     PISSN: 18324274     EISSN: None     Source Type: Journal    
DOI: 10.1375/twin.12.3.269     Document Type: Article

References (34)

1. Balasubramanian, S. P., Brown, N. J., & Reed, M. W. (2002). Role of genetic polymorphisms in tumor angiogenesis. British Journal of Cancer, 87, 1057-1065. (Pubitemid 35418098)
2. Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265. (Pubitemid 40202029)
3. Bikfalvi, A., Klein, S., Pintucci, G., & Rifkin, D. B. (1997). Biological roles of fibroblast growth factor-2. Endocrine Reviews, 18, 26-45. (Pubitemid 27076454)
4. Boyd, J., & Rubin, S. C. (1997). Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecologic Oncology, 64, 196-206. (Pubitemid 27097566)
5. Cannistra, S. A. (1993). Cancer of the ovary. New England Journal of Medicine, 329(21), 1550-1559. (Pubitemid 23332443)
6. Carlson, C. S., Eberle, M. A., Rieder, M. J., Yi, Q., Kruglyak, L., & Nickerson, D. A. (2004). Selecting a Maximally Informative Set of Single-Nucleotide Polymorphisms for Association Analyses Using Linkage Disequilibrium. The American Journal of Human Genetics, 74, 106-120. (Pubitemid 38085242)
7. Crickard, K., Gross, J. L., Crickard, U., Yoonessi, M., Lele, S., Herblin, W. F., et al. (1994). Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecologic Oncology, 55, 277-284. (Pubitemid 24366639)
8. de Bakker, P. I., Yelensky, R., Pe'er, I., Gabriel, S. B., Daly, M. J., & Altshuler, D. (2005). Efficiency and power in genetic association studies. Nature Genetics, 37, 1217-1223.
9. De Cecco, L., Marchionni, L., Gariboldi, M., Reid, J. F., Lagonigro, M. S., Caramuta, S., Ferrario, C., Bussani, E., Mezzanzanica, D., Turatti, F., Delia, D., Daidone, M. G., Oggionni, M., Bertuletti, N., Ditto, A., Raspagliesi, F., Pilotti, S., Pierotti, M. A., Canevari, S., & Schneider, C. (2004). Gene expression profiling of advanced ovarian cancer: Characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 23, 8171-8183. (Pubitemid 39531858)
10. Dow, J. K., & deVere White, R. W. (2000). Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology, 55, 800-806.
11. Edlund, C., Lee, W., Li, D., Van Den Berg, D., & Conti, D. (2008). Snagger: A user-friendly program for incorporating additional information for tagSNP selection. BMC Bioinformatics, 9, 174. (Pubitemid 351619256)
12. Folkman, J., & Klagsbrun, M. (1987). Angiogenic factors. Science, 235(4787), 442-447. (Pubitemid 17009577)
13. Gayther, S. A., de Foy, K. A., Harrington, P., Pharoah, P., Dunsmuir, W. D., Edwards, S. M., Gillett, C., Ardern-Jones, A., Dearnaley, D. P., Easton, D. F., Ford, D., Shearer, R. J., Kirby, R. S., Dowe, A. L., Kelly, J., Stratton, M. R., Ponder, B. A., Barnes, D., & Eeles, R. A. (2000). The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Research, 60, 4513-4518.
14. Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., Frazer, K. A., & Cox, D. R. (2005). Whole-genome patterns of common DNA variation in three human populations. Science, 307, 1072-1079. (Pubitemid 40262106)
15. Hollingsworth, H. C., Kohn, E. C., Steinberg, S. M., Rothenberg, M. L., & Merino, M. J. (1995). Tumor angiogenesis in advanced stage ovarian carcinoma. American Journal of Pathology, 147, 33-41.
16. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., & Kozai, Y. (1991). Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Research, 51, 6180-6184.
17. The International HapMap Project. (2003). Nature, 426, 789-796.
18. Macchiarini, P., Fontanini, G., Hardin, M. J., Squartini, F., & Angeletti, C. A. (1992). Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 340, 145-146.
19. Merritt, M. A., Green, A. C., Nagle, C. M., & Webb, P. M. (2007). Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. International Journal of Cancer, 122, 170-176.
20. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., & Folkman, J. (1994). Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. Journal of the National Cancer Institute, 86, 356-361. (Pubitemid 24076875)
21. Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA A Cancer Journal for Clinicians, 55, 74-108. (Pubitemid 40372904)
22. Pearce, C. L., Wu, A. H., Gayther, S. A., Bale, A. E., Beck, P. A., Beesley, J., et al. (2008). Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: Results from the Ovarian Cancer Association Consortium pooled analysis. British Journal of Cancer, 98, 282-288. (Pubitemid 351161257)
23. Pharoah, P. D., & Ponder, B. A. (2002). The genetics of ovarian cancer. Best Practice & Research: Clinical Obstetrics & Gynaecology, 16, 449-468. (Pubitemid 41123401)
24. Pike, M. C., Pearce, C. L., Peters, R., Cozen, W., Wan, P., & Wu, A. H. (2004). Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertility and Sterility, 82, 186-195. (Pubitemid 38968797)
25. Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000). Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer, 7, 165-197. (Pubitemid 30797575)
26. Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine & Growth Factor Reviews, 16, 159-178. (Pubitemid 40616114)
27. Purcell, S., Cherny, S. S., & Sham, P. C. (2003). Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics, 19, 149-150. (Pubitemid 36150192)
28. Rossing, M. A., Cushing-Haugen, K. L., Wicklund, K. G., Doherty, J. A., & Weiss, N. S. (2007). Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiology Biomarkers & Prevention, 16, 2548-2556. (Pubitemid 351196308)
29. Sellers, T. A., Huang, Y., Cunningham, J., Goode, E. L., Sutphen, R., Vierkant, R. A., Kelemen, L. E., Fredericksen, Z. S., Liebow, M., Pankratz, V. S., Hartmann, L. C., Myer, J., Iversen, E. S. Jr., Schildkraut, J. M., & Phelan, C. (2008). Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiology Biomarkers & Prevention, 17, 397-404. (Pubitemid 351272793)
30. Weidner, N. (1995). Intratumor microvessel density as a prognostic factor in cancer. American Journal of Pathology, 147, 9-19.
31. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., & Folkman, J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. American Journal of Pathology, 143, 401-409. (Pubitemid 24058195)
32. Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991). Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1-8.
33. Wenham, R. M., Lancaster, J. M., & Berchuck, A. (2002). Molecular aspects of ovarian cancer. Best Practice & Research: Clinical Obstetrics & Gynaecology, 16, 483-497. (Pubitemid 41123403)
34. Whittemore, A. S. (1994). Characteristics relating to ovarian cancer risk: Implications for prevention and detection. Gynecologic Oncology, 55, S15-19.